Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 0.99
23.8 %
$ 15.3 M
Market Cap
None
P/E
CASH FLOW STATEMENT
-6.04 M
OPERATING CASH FLOW
-2.21 M
INVESTING CASH FLOW
-345 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
bioAffinity Technologies, Inc.
| Net Income | -7.94 M |
| Depreciation & Amortization | 250 K |
| Capital Expenditures | -22.9 K |
| Stock-Based Compensation | 749 K |
| Change in Working Capital | 901 K |
| Others | 604 K |
| Free Cash Flow | -6.06 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (7.9) | (8.2) | (6.3) | (7.3) | (3.3) |
| Depreciation & Amortization | 0.2 | 10.2 K | 4.82 K | 22.2 K | 40.3 K |
| Deferred Income Tax | 0 | 0 | 3.8 | 0 | 0 |
| Stock Based Compensation | 0.7 | 0.2 | 43 K | 0.3 | 0 |
| Other Operating Activities | 0 | 3.7 | (0.2) | 4.3 | 0.6 |
| Change in Working Capital | 0.9 | 0.1 | 0.6 | 0.5 | 0.3 |
| Cash From Operations | (6.0) | (4.1) | (2.0) | (2.2) | (2.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 22.9 K | (0.2) | 0 | 2.89 K | 11.4 K |
| Other Items | (2.2) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (2.2) | (0.2) | 0 | 2.89 K | 11.4 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (0.3) | 0.6 | 0.2 | 0.2 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 7.7 | 3.1 | 1.5 | 2.3 |
| Cash From Financing Activities | (0.3) | 14.3 | 3.3 | 1.7 | 2.3 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (8.6) | 10.1 | 1.3 | (0.5) | (0.2) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (6.1) | (4.3) | (2.0) | (2.2) | (2.5) |